Bulk Anti-Cancer CAS 159351-69-6 Everolimus Raw Material Everolimus Powder Everolimus

• Powder: Yes
• Customized: Customized
• Certification: GMP, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >98%
• Model NO.: TGY2022050508
• Product Name: Everolimus
• Appearance: White Crystalline Powder
• Molecular Formula: C53h83no14
• MW: 958.22
• CAS No.: 159351-69-6
• Einecs No: 621-003-9
• Storage: Cool Dry Area
• Shelf Life: 24 Months
• Sample: Avaliable
• Service: OEM
• Assay: 98%Min, 99% HPLC
• COA: Available
• Grade: Pharmaceutical Grade
• Test Method: UV/HPLC
• Other Name: Everolimus Powder
• Transport Package: Boil Bag
• Specification: HPLC 99%
• Trademark: TGY
• Origin: Xi′an, Shaanxi, China
• HS Code: 29379000
• Production Capacity: 800kg/Month

Product Description

Product Name: Everolimus

CAS No.:159351-69-6

Molecular Formula: C53H83NO14

Molecular Weight: 958.22g/mol

Purity : 99%

Appearance:  White Crystalline Powder

Typical use:Novel immunosuppressants

Standard Packing : 1gram,10gram,100gram

Shelf Life :2 years

Storage:Room temperature away from light

 

Everolimus is used to treat advanced (late-stage) cancers or noncancerous tumors, such as kidney and breast cancer, subependymal giant cell astrocytoma (SEGA, a brain tumor), renal angiomyolipoma (kidney tumor), and partial-onset seizures (epilepsy) with tuberous sclerosis complex (TSC), and neuroendocrine tumors of the pancreas, stomach or bowels, and lungs. It is used for patients who have already received other medicines that did not work well or those who will not be treated with surgery.

Everolimus works by interfering with the growth of cancer cells, which are eventually destroyed by the body. Since the growth of normal body cells may also be affected, other unwanted effects will also occur. It belongs to the group of medicines known as antineoplastics (cancer medicines).

Everolimus is also used together with other medicines to lower the body's natural immunity in patients who receive kidney or liver transplants. When a patient receives an organ transplant, the body's white blood cells try to get rid of (reject) the transplanted organ. Everolimus works to suppress the immune system and prevents the white blood cells from getting rid of the transplanted organ.
Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination. Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease. Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.